Skip to content
Home / Companies / MANE MAN
Veradermics, Inc (MANE) XNYS PHARMACEUTICAL PREPARATIONS Net insider selling (90d)
Latest MANE Insider Trades
About Veradermics, Inc (MANE) Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
Headquarters NEW HAVEN, CT
Employees 21
Listed 2026
Exchange XNYS https://www.veradermics.com SEC filings for MANE on EDGAR
90-Day SEC Filing Activity Form 4 transaction type Transactions Shares Total value Open-market sale 15 961,000 $103.12M Option exercise 4 13,808 Other acquisition / disposition 4 600,000
MANE Insider Transactions (Form 4) 101 19 Form 4 filings on record, the earliest from Feb 6, 2026, newest first.
Recent MANE Form 8-K Filings 5
Recent MANE Form 144 Notices of Proposed Sale 3 A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
Filed Filer Relationship Shares Market value Notice Aug 19, 2026 Averill Master Fund, Ltd. Affiliate 690,601 $74.07M View on EDGAR Aug 19, 2026 Averill Madison Master Fund, Ltd. Affiliate
MANE Insider Trading - FAQ
What is the latest insider trade for MANE? Veradermics, Inc (MANE) had 4 insider filings in the last 90 days, with the most recent on 2026-08-21. The full record for MANE runs to 19 Form 4 filings, the earliest from 2026-02-06. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying MANE stock? No insider purchases of MANE were filed in the last 90 days. 27 purchases are on record for this company.
How many insiders are selling MANE stock? 15 insider sales of MANE were filed in the last 90 days, totaling $103.12M.
Where can I see MANE SEC filings (Form 4, 10-K, 10-Q, 8-K)? This page tracks MANE Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow MANE insider buys? Create a free InsiderAlpha account and press Watch on this page to add MANE to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Companies with Insider Activity Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Aug 21, 2026 - SUVRETTA CAPITAL MANAGEMENT, LLC view on EDGAR Aug 19, 2026 - Timothy August Durso view on EDGAR Aug 19, 2026 - Reid Alexander Waldman view on EDGAR Aug 14, 2026 - John W. Childs view on EDGAR May 6, 2026 - SUVRETTA CAPITAL MANAGEMENT, LLC view on EDGAR Feb 27, 2026 - John W. Childs view on EDGAR Feb 9, 2026 - SUVRETTA CAPITAL MANAGEMENT, LLC view on EDGAR Feb 6, 2026 - Katarina Pance view on EDGAR Feb 6, 2026 - Jane M. Grant-Kels view on EDGAR What is SEC Form 4? The filing insiders must submit within two business days of a trade, and how to read its transaction codes. Track MANE insider activity as it files Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
Sign up free Aug 19, 2026
Market cap $4.09B
P/E ratio -
Dividend yield -
Average volume 723.1K
52 week high $131.24
52 week low $32.00
Today's high $102.41
Today's low $97.00
Open $102.30
Volume 623.7K
Previous close $101.81
Shares outstanding 41.78M Market cap
$4.09B
21 employees
MANE Insider Sentiment - Last 90 Days Share of open-market insider dollar volume that was buying versus selling, from SEC Form 4 filings.
0% Buying 100% Selling
0 insider purchases totaling $0 against 15 sales totaling $103.12M.
Most-Active MANE Insiders - Last 90 Days 10 Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Aug 12, 2026 JC John W. Childs - Director Open-market sale Common Stock 15,000 $106.14 $1.59M
Aug 12, 2026 JC John W. Childs - Director Open-market sale Common Stock 80,000 $107.23 $8.58M
Aug 12, 2026 JC John W. Childs - Director Open-market sale Common Stock 5,000 $108.24 $541K
Feb 5, 2026 JC John W. Childs - Director Open-market purchase Common Stock 294,117 $17.00 $5.00M
Feb 3, 2026 KP Katarina Pance Grant or award Stock Option (Right to Buy) 43,000 $0.00 -
Feb 5, 2026 JG Jane M. Grant-Kels - Director Other Series A Convertible Preferred Stock 2,455 - -
Feb 3, 2026 JG Jane M. Grant-Kels - Director Grant or award Stock Option (Right to Buy) 51,525 $0.00 -
Feb 5, 2026 VC Vlad Coric - Director Other Common Stock 33,706 - -
Feb 5, 2026 VC Vlad Coric - Director Other Common Stock 33,706 - -
Feb 5, 2026 VC Vlad Coric - Director Other Common Stock 148,794 - -
Feb 5, 2026 VC Vlad Coric - Director Other Common Stock 148,794 - -
Feb 5, 2026 VC Vlad Coric - Director Other Common Stock 78,075 - -
Feb 5, 2026 VC Vlad Coric - Director Other Common Stock 78,075 - -
Feb 5, 2026 VC Vlad Coric - Director Other Common Stock 117,112 - -
Feb 5, 2026 VC Vlad Coric - Director Open-market purchase Common Stock 58,823 $17.00 $1.00M
Feb 5, 2026 VC Vlad Coric - Director Open-market purchase Common Stock 58,823 $17.00 $1.00M
Feb 5, 2026 VC Vlad Coric - Director Other Series A Convertible Preferred Stock 33,706 - -
Feb 5, 2026 VC Vlad Coric - Director Other Series A Convertible Preferred Stock 33,706 - -
Feb 5, 2026 VC Vlad Coric - Director Other Series B Convertible Preferred Stock 148,794 - -
Feb 5, 2026 VC Vlad Coric - Director Other Series B Convertible Preferred Stock 148,794 - -
Feb 5, 2026 VC Vlad Coric - Director Other Series C Convertible Preferred Stock 78,075 - -
Feb 5, 2026 VC Vlad Coric - Director Other Series C Convertible Preferred Stock 78,075 - -
Feb 5, 2026 VC Vlad Coric - Director Other Series C Convertible Preferred Stock 117,112 - -
Feb 3, 2026 VC Vlad Coric - Director Grant or award Stock Option (Right to Buy) 51,525 $0.00 -
Feb 5, 2026 JC John W. Childs - Director Open-market purchase Common Stock 294,117 $17.00 $5.00M
Feb 5, 2026 JC John W. Childs - Director Other Series A Convertible Preferred Stock 480,269 - -
Feb 5, 2026 JC John W. Childs - Director Other Series B Convertible Preferred Stock 906,862 - -
Feb 5, 2026 JC John W. Childs - Director Other Series C Convertible Preferred Stock 520,758 - -
Feb 3, 2026 JC John W. Childs - Director Grant or award Stock Option (Right to Buy) 51,525 $0.00 -
Feb 5, 2026 PE Patrick G. Enright - Director Open-market purchase Common Stock 192,647 $17.00 $3.27M
Feb 5, 2026 PE Patrick G. Enright - Director Open-market purchase Common Stock 882,353 $17.00 $15.00M
Feb 5, 2026 PE Patrick G. Enright - Director Other Series B Convertible Preferred Stock 1,236,631 - -
Feb 5, 2026 PE Patrick G. Enright - Director Other Series C Convertible Preferred Stock 1,171,121 - -
Feb 5, 2026 PE Patrick G. Enright - Director Other Series C Convertible Preferred Stock 1,171,121 - -
Feb 3, 2026 PE Patrick G. Enright - Director Grant or award Stock Option (Right to Buy) 45,131 $0.00 -
Feb 3, 2026 MG Michael V. Greco - Officer Grant or award Stock Option (Right to Buy) 144,401 $0.00 -
Feb 3, 2026 MN Mark Neumann - Officer Grant or award Stock Option (Right to Buy) 102,885 $0.00 -
